hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06309784, orgStudyIdInfo id: RD 2595, secondaryIdInfos id: NIHR II-LA-1116-20004, type: OTHER_GRANT, domain: NIHR, briefTitle: Development of a Drill Guidance System to Aid Intra-operative Surgical Drilling, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Royal United Hospitals Bath NHS Foundation Trust, class: OTHER, collaborators name: University of Bath, collaborators name: Great Western Hospitals NHS Foundation Trust, descriptionModule briefSummary: The Investigators have developed a camera based drill guidance system to improve the accuracy of surgical drilling. The aim of the study is to assess:Accuracy in vivo Safety Acceptability of use amongst surgeons and theatre staff, conditionsModule conditions: Orthopaedic Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Participants undergoing orthopaedic Surgery, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Drill Guidance System (DGS), outcomesModule primaryOutcomes measure: Accuracy of placement of a screw or K wire in scaphoid bones, primaryOutcomes measure: Accuracy of placement of a screw or K wire in other bones, secondaryOutcomes measure: Length of material part of the procedure, secondaryOutcomes measure: Number of fluoroscopy (perioperative X-ray) images performed, secondaryOutcomes measure: Number of patients with treatment related adverse events as assessed by CTCAE v4.0, secondaryOutcomes measure: Immediate acceptability to surgeons and theatre staff, secondaryOutcomes measure: Initial acceptability to surgeons and theatre staff, secondaryOutcomes measure: Overall acceptability to surgeons and theatre staff, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Royal United hospitals NHS Foundation Trust, status: RECRUITING, city: Bath, country: United Kingdom, contacts name: Jane Carter, BSc, role: CONTACT, phone: 01225821095, email: jane.carter14@nhs.net, geoPoint lat: 51.3751, lon: -2.36172, locations facility: Great Western Hospital MHS foundation Trust, status: RECRUITING, city: Swindon, country: United Kingdom, contacts name: Adam Smith, FRCS, role: CONTACT, phone: 07533793889, email: adam.smith@doctors.org.uk, geoPoint lat: 51.55797, lon: -1.78116, hasResults: False
protocolSection identificationModule nctId: NCT06309745, orgStudyIdInfo id: THERATEST, briefTitle: THERApy De-escalation for TESTicular Cancer, acronym: THERATEST, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2027-05, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Queen Mary University of London, class: OTHER, descriptionModule briefSummary: THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies., conditionsModule conditions: Seminoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: retroperitoneal lymph node dissection, interventions name: Carboplatin AUC10, outcomesModule primaryOutcomes measure: FEASIBILITY of recruitment and retention, secondaryOutcomes measure: QUALITY OF LIFE assessed by difference in HRQOL scores, secondaryOutcomes measure: QUALITY OF LIFE assessed by difference in differences in sexual drive, function, and overall satisfaction, secondaryOutcomes measure: Progression free SURVIVAL, secondaryOutcomes measure: OVERALL SURVIVAL, secondaryOutcomes measure: SAFETY and complication of all treatments, eligibilityModule sex: MALE, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Barts and London Hospital NHS Trust, status: RECRUITING, city: London, country: United Kingdom, contacts name: THERATEST Study coordinator, role: CONTACT, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06309732, orgStudyIdInfo id: 4491, secondaryIdInfos id: 2006-001963-52, type: EUDRACT_NUMBER, secondaryIdInfos id: TE 2006-09, type: OTHER, domain: Barts and the London NHS Trust, briefTitle: GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT), acronym: GAMEC-II, statusModule overallStatus: COMPLETED, startDateStruct date: 2006-07, primaryCompletionDateStruct date: 2013-06, completionDateStruct date: 2014-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Queen Mary University of London, class: OTHER, descriptionModule briefSummary: St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin). The results of this study showed that 50% of patients with relapsed testicular cancer could be cured using this treatment. These results are very encouraging and compare very favourably to other treatment protocols. In reviewing this study, it became clear that of the 5 cycles of treatment which were proposed, the first 3 seemed to matter and the last 2 did not appear important. In addition there was a group of patients who appeared to do particularly well namely patients under the age of 35 and those who had a normal LDH (lactate dehydrogenase). LDH is a blood test which monitors cancer activity. Selecting patients which fill both these criteria, this trial aims to see whether the investigators can maintain the good results the investigators have seen but using only 3 cycles of treatment. This will therefore shorten the treatment from 10 weeks to 6 weeks, thus reducing the side effects., conditionsModule conditions: Testicular Neoplasms, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: Pegfilgrastim, interventions name: Dactinomycin, interventions name: Methotrexate, interventions name: Etoposide, interventions name: Cisplatin, interventions name: Epirubicin, outcomesModule primaryOutcomes measure: Response rate to GAMEC-S or GAMEC-A, secondaryOutcomes measure: Relapse-free survival, secondaryOutcomes measure: Overall survival, eligibilityModule sex: MALE, minimumAge: 16 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Barts and the London NHS Trust, city: London, zip: EC1A 7BE, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06309706, orgStudyIdInfo id: JXHU, briefTitle: A Retrospective Cone Beam Computed Tomography Study of The Lateral Wall Bony Window, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-09-01, primaryCompletionDateStruct date: 2020-01-01, completionDateStruct date: 2020-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: The Dental Hospital of Zhejiang University School of Medicine, class: OTHER, descriptionModule briefSummary: Three experienced observers were asked to screen all the CBCT images from the Stomatology Hospital,Zhejiang University School of Medicine, between September 1, 2019 and December 31, 2019, and counted 1000 maxillary sinus CBCT images that met the criteria. Later, 1000 CBCT images were further measured and analyzed, and indicators such as maxillary sinus buccal wall thickness, morphology, whether there is blood vessel or not, whether there is bone septa or not were counted. The variation rules and related factors were summarized by SPSS analysis., conditionsModule conditions: Lateral Wall Thickness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1000, type: ACTUAL, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Lateral wall thickness, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06309680, orgStudyIdInfo id: 280992, briefTitle: Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients, acronym: AMetIP, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-24, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Queen Mary University of London, class: OTHER, collaborators name: Barts & The London NHS Trust, collaborators name: Quadram Institute Bioscience, descriptionModule briefSummary: Infective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs.We are very keen to improve the treatment of this disease and we are measuring the impact of the treatments that we give to patients so that we have a very clear idea of which treatments work best and also which treatments are less successful.A key part of the treatment is the accurate determination of the causative organism which allows appropriate targeted antibiotic and antifungal medication to be administered.Accurate antibiotic regimes require detection of the causative organism and its sensitivities to each antibiotic. Antibiotic choice is then based on effectiveness, toxicity, ease of use and national guidelines. The current best technique for identifying bacteria is blood culture where organisms are identified by growing them from blood samples. However, this takes up to 5 days from sampling, resulting in delays to the correct diagnosis. Until this time, treatment requires the use of generic, more toxic antibiotic regimes.New techniques are emerging to identify causative organisms from blood. Metagenomics allows the sequencing of bacterial DNA allowing precise identification of the infecting organism., conditionsModule conditions: Infective Endocarditis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: diagnostic accuracy of CMg in blood, secondaryOutcomes measure: to evaluate the results of Nanopore CMg in identifying the causative organism in patients with BCNIE, secondaryOutcomes measure: 1. Optimal timing of blood sampling, secondaryOutcomes measure: 3. Metagenomic Techniques, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St Bartholomew's Hospital. West Smithfield, status: RECRUITING, city: London, zip: EC1A 7BE, country: United Kingdom, contacts name: Innocent M Bvekerwa, role: CONTACT, phone: 07852209005, email: i.bvekerwa@nhs.net, contacts name: Simon Woldman, role: CONTACT, email: simon.woldman@nhs.net, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06309641, orgStudyIdInfo id: MetHb 001, briefTitle: Methemoglobinemia Following Intravenous Iron Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Claudia Seiler, class: OTHER, descriptionModule briefSummary: Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose., conditionsModule conditions: Methemoglobinemia, conditions: Anemia, conditions: Iron Deficiencies, conditions: Side Effect, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Blood sample after treatment, interventions name: Case reports, outcomesModule primaryOutcomes measure: Difference in methemoglobin after ferric derisomaltose, primaryOutcomes measure: Difference in methemoglobin after ferric carboxymaltose, secondaryOutcomes measure: Difference in methemoglobin depending on drug dosage, secondaryOutcomes measure: Difference in methemoglobin depending on age, secondaryOutcomes measure: Difference in methemoglobin depending on sex, secondaryOutcomes measure: Difference in methemoglobin depending on hemoglobin level before treatment, secondaryOutcomes measure: Difference in methemoglobin depending on blood levels of ferritin, transferrin or iron., secondaryOutcomes measure: Association between difference in methemoglobin and venous lactate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Center of Clinical Research Dalarna, city: Falun, zip: 79182, country: Sweden, contacts name: Claudia Seiler, MD, role: CONTACT, phone: +46 70 2896416, email: claudia.seiler@regiondalarna.se, geoPoint lat: 60.60357, lon: 15.62597, hasResults: False
protocolSection identificationModule nctId: NCT06309628, orgStudyIdInfo id: PGX-006, briefTitle: Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-09-21, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Paragonix Technologies, class: INDUSTRY, collaborators name: Picomole Inc, descriptionModule briefSummary: This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy., conditionsModule conditions: Lung Transplant Rejection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Breathe sample, outcomesModule primaryOutcomes measure: Volatile Organic Compound profile, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Duke University, city: Durham, state: North Carolina, zip: 27710, country: United States, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06309615, orgStudyIdInfo id: PDX-001_2, briefTitle: Decision Impact Study of PreciseDx Breast, acronym: PDxBRUTILITY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2029-05-30, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Precise Dx, Inc., class: INDUSTRY, collaborators name: The Cleveland Clinic, descriptionModule briefSummary: The investigator's developed a digital LDT to predict invasive breast cancer (IBC) recurrence within 6 years by combining histologic features extracted from an H\&E image of the patients IBC with clinical data including the patients age, tumor size, stage and number of positive lymph nodes. The development of an artificial-intelligent (AI)-grade provides not only an objective, quantitative advancement of classical breast cancer grading but also improves upon the accuracy and utility of clinical risk. The investigator's sought to understand how such a PreciseDx Breast would be used in clinical practice post-surgical resection for women with early-stage IBC., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Standard of Care, outcomesModule primaryOutcomes measure: Decision Impact Study of PreciseDx Breast on treating Oncologist, primaryOutcomes measure: Decision Impact Study of PreciseDx Breast on Diagnostic Pathologist, secondaryOutcomes measure: Decision Impact on long term outcomes, eligibilityModule sex: FEMALE, minimumAge: 23 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06309602, orgStudyIdInfo id: 22-0465, briefTitle: Investigation of a Free Water Protocol, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2028-01-01, completionDateStruct date: 2028-01-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Poudre Valley Health System, class: OTHER, descriptionModule briefSummary: Hypothesis: Use of a Free Water Protocol (FWP) will improve patient satisfaction scores (Dysphagia Handicap Index), will not increase the risk of aspiration pneumonia/pneumonitis, and will result in improved oral hygiene (as assessed by the Oral Assessment Guide). Aim: To demonstrate that improvement in patient satisfaction and quality of life scores outweighs the potential risks of aspiration of plain water in an acute care setting; to qualitatively assess the implementation of a Free Water Protocol from the viewpoints of the patient and family/caregivers; to quantify changes in oral hygiene practices for individuals on the Free Water Protocol., conditionsModule conditions: Oropharyngeal Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 136, type: ESTIMATED, armsInterventionsModule interventions name: Free Water Protocol, interventions name: Control / Standard Care, outcomesModule primaryOutcomes measure: Dysphagia Handicap Index, primaryOutcomes measure: Oral Assessment Guide, primaryOutcomes measure: Qualitative data, secondaryOutcomes measure: Adverse events: Aspiration pneumonia/pneumonitis, secondaryOutcomes measure: Liquid intake, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Center of the Rockies, city: Loveland, state: Colorado, zip: 80538, country: United States, contacts name: Emily Main, MS, CCC-SLP, role: CONTACT, phone: 970-624-4369, email: emily.main@uchealth.org, contacts name: Brian Daily, MD, role: SUB_INVESTIGATOR, contacts name: Cordelie Witt, MD, role: SUB_INVESTIGATOR, contacts name: Lucie Uncapher, MD, role: SUB_INVESTIGATOR, contacts name: Brandon Petrun, MD, role: SUB_INVESTIGATOR, geoPoint lat: 40.39776, lon: -105.07498, hasResults: False
protocolSection identificationModule nctId: NCT06309589, orgStudyIdInfo id: YIHM, briefTitle: The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-01, primaryCompletionDateStruct date: 2023-09-30, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Yilihamu·Abilitifu, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare in the effectiveness of combining ursodeoxycholic acid and vitamin D in treating patients with primary biliary cholangitis., conditionsModule conditions: Primary Biliary Cholangitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Vitamin D, outcomesModule primaryOutcomes measure: UDCA response: Paris I criteria, primaryOutcomes measure: UDCA response: Barcelona criteria, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: People's Hospital of Xinjiang Uygur Autonomous Region, city: Urumqi, state: Xinjiang, zip: 830001, country: China, geoPoint lat: 43.80096, lon: 87.60046, hasResults: False